922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; pp. S582 - S583
Main Authors: Hanna, G.J., Kaczmar, J., Zandberg, D.P., Wong, D.J., Yilmaz, E., Sherman, E.J., Hernando Calvo, A., Sacco, A.G., Bohr, D., Reiners, R., Bilic, S., Salazar, R., Gharakhani, E., Chung, C.H.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.2066